Infliximab

DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.

PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.

After 26 weeks of retreatment with infliximab, 35% of patients with Crohn’s disease achieved remission, according to recent data.

After previously discontinuing infliximab, 35% of patients with Crohn’s disease achieved remission at 26 weeks with drug retreatment, according to a study published in The American Journal of Gastroenterology.

Immunosuppressed patients with inflammatory bowel disease who received a third COVID-19 vaccine demonstrated improved antibody binding, although the response was reduced in patients receiving infliximab and tofacitinib.

Although biosimilar-to-biosimilar switching is not covered by health regulations or guidance, a systematic literature review suggests the practice is safe and effective, according to data published in BioDrugs.

Use of biologics did not worsen stable SARS-CoV-2 infection in patients with inflammatory bowel disease if given within 2 weeks of virus detection, according to research published in Clinical Gastroenterology and Hepatology.

The use of infliximab in patients with a deceased donor kidney transplant led to increased infections and did not improve allograft survival, according to data presented at the American Transplant Congress.

SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who switched from IV dosing, according to research presented at Digestive Disease Week.

In this video, Haley Naik, MD, discusses “three key themes” from the hidradenitis suppurativa symposiums at the American Academy of Dermatology Annual Meeting.